NCT03604211

SBRT for Oligometastatic Lymph Node Recurrence in Prostate Cancer: a Single Institution Experience

Predictive Factors for the Benefit of Stereotactic Body Radiotherapy for Oligometastatic Lymph Node Recurrence in Prostate Cancer: a Single Institution Experience

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 25 (actual)
• Sponsor: Kantonsspital Graubuenden · Academic / Other
• Sex: Male
• Age: 18 Years – 85 Years
• Healthy volunteers: —

Summary

Single-institution retrospective analysis for predictive factors of prostate cancer patients presenting with isolated or limited lymph node (LN) recurrence (1-3 lesions) on F-Ccholine PET-CT (CholPET) treated with SBRT between January 2010 and July 2015.

Detailed description

Single-institution retrospective analysis of consecutive prostate cancer patients after definitive primary treatment, without local recurrence, presenting with isolated or limited lymph node (LN) recurrence (1-3 lesions) on F-Ccholine PET-CT (CholPET) treated with SBRT between January 2010 and July 2015. Endpoints of interest are biochemical response rate (defined as a reduction by at least 10% of the initial PSA value), time to biochemical recurrence (TBR) (defined as the time interval from SBRT until second PSA rise), and time interval between SBRT and ADT start. Univariate analysis is used to identify prognostic factors.

Conditions

• Prostate Cancer Recurrent
• Prostate Cancer
• Lymph Node Metastases

Interventions

Type	Name	Description
RADIATION	Cyberknife Radiation Therapy	Stereotactic Radiotherapy of lymphnode recurrence after prostatectomy +/- salvage radiotherapy

Timeline

• Start date: 2010-01-01
• Primary completion: 2015-07-01
• Completion: 2018-07-01
• First posted: 2018-07-27
• Last updated: 2018-08-17

Locations

1 site across 1 country: Switzerland